Literature DB >> 11071856

Identification of novel first exons in Ad4BP/SF-1 (NR5A1) gene and their tissue- and species-specific usage.

R Kimura1, H Yoshii, M Nomura, N Kotomura, T Mukai, S Ishihara, K Ohba, T Yanase, O Gotoh, H Nawata, K Morohashi.   

Abstract

It has been demonstrated that the mammalian Ad4BP/SF-1 (NR5A1) gene is regulated precisely in sex, tissue, and developmental stage specific manners. To clarify the complex transcriptional regulation, we investigated in the present study whether the gene transcription is regulated by multiple promoters accompanied by noncoding first exons. Novel first exons (Io and Ig) were identified downstream of the already identified exon Ia. Nucleotide sequences revealed that Ia and Ig exons were well conserved, whereas Io exon was less conserved among the mouse, rat, and human genes. Interestingly, the splice donor of the mouse and human Io and human Ig exons do not satisfy the consensus sequence. Transcripts containing Ia, Io, and Ig were detected in all rat tissues examined, while the transcript containing Io was undetectable in the corresponding tissues of mice. The lack of exon Io usage in the mouse was confirmed by transient transfection assays with cultured cells. Quantitative RT-PCR analysis revealed that the transcript containing Ig exon was the main product in the pituitary but significantly less in the spleen, suggesting that the regulation of Ad4BP/SF-1 gene transcription in the pituitary and spleen is distinct from that of other tissues. The above findings, together with the structural abnormality at the splice donor site, suggest that acquisition of the multiple first exons enables the Ad4BP/SF-1 gene to be regulated differentially in different animal species and in different tissues in the same animal. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071856     DOI: 10.1006/bbrc.2000.3774

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Two-step regulation of Ad4BP/SF-1 gene transcription during fetal adrenal development: initiation by a Hox-Pbx1-Prep1 complex and maintenance via autoregulation by Ad4BP/SF-1.

Authors:  Mohamad Zubair; Satoru Ishihara; Sanae Oka; Katsuzumi Okumura; Ken-ichirou Morohashi
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

2.  Pituitary homeobox 2 regulates adrenal4 binding protein/steroidogenic factor-1 gene transcription in the pituitary gonadotrope through interaction with the intronic enhancer.

Authors:  Yuichi Shima; Mohamad Zubair; Tomoko Komatsu; Sanae Oka; Chikako Yokoyama; Taro Tachibana; Tord A Hjalt; Jacques Drouin; Ken-ichirou Morohashi
Journal:  Mol Endocrinol       Date:  2008-04-16

3.  Alternative splicing and expression of human and mouse NFAT genes.

Authors:  Hanna Vihma; Priit Pruunsild; Tõnis Timmusk
Journal:  Genomics       Date:  2008-08-26       Impact factor: 5.736

4.  The novel p.Cys65Tyr mutation in NR5A1 gene in three 46,XY siblings with normal testosterone levels and their mother with primary ovarian insufficiency.

Authors:  Helena Campos Fabbri; Juliana Gabriel Ribeiro de Andrade; Fernanda Caroline Soardi; Flávia Leme de Calais; Reginaldo José Petroli; Andréa Trevas Maciel-Guerra; Gil Guerra-Júnior; Maricilda Palandi de Mello
Journal:  BMC Med Genet       Date:  2014-01-10       Impact factor: 2.103

5.  Identification of a pituitary ERα-activated enhancer triggering the expression of Nr5a1, the earliest gonadotrope lineage-specific transcription factor.

Authors:  Vincent Pacini; Florence Petit; Bruno Querat; Jean-Noël Laverriere; Joëlle Cohen-Tannoudji; David L'hôte
Journal:  Epigenetics Chromatin       Date:  2019-08-07       Impact factor: 4.954

6.  Conserved usage of alternative 5' untranslated exons of the GATA4 gene.

Authors:  Séverine Mazaud Guittot; Marie France Bouchard; Jean-Philippe Robert-Grenon; Claude Robert; Cynthia G Goodyer; David W Silversides; Robert S Viger
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.